Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR)
Publication
, Conference
Devine, S; Kattan, MW; Muir, AJ; Pedicone, L; Poordad, F; Poynard, T; Sulkowski, MS; Thompson, AJ
Published in: HEPATOLOGY
October 1, 2012
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
1052A / 1052A
Location
Boston, MA
Publisher
WILEY
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Devine, S., Kattan, M. W., Muir, A. J., Pedicone, L., Poordad, F., Poynard, T., … Thompson, A. J. (2012). Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR). In HEPATOLOGY (Vol. 56, pp. 1052A-1052A). Boston, MA: WILEY.
Devine, Scott, Michael W. Kattan, Andrew J. Muir, Lisa Pedicone, Fred Poordad, Thierry Poynard, Mark S. Sulkowski, and Alexander J. Thompson. “Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR).” In HEPATOLOGY, 56:1052A-1052A. WILEY, 2012.
Devine S, Kattan MW, Muir AJ, Pedicone L, Poordad F, Poynard T, et al. Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR). In: HEPATOLOGY. WILEY; 2012. p. 1052A-1052A.
Devine, Scott, et al. “Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR).” HEPATOLOGY, vol. 56, WILEY, 2012, pp. 1052A-1052A.
Devine S, Kattan MW, Muir AJ, Pedicone L, Poordad F, Poynard T, Sulkowski MS, Thompson AJ. Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR). HEPATOLOGY. WILEY; 2012. p. 1052A-1052A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2012
Volume
56
Start / End Page
1052A / 1052A
Location
Boston, MA
Publisher
WILEY
Conference Name
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics